MetLife Investment Management’s Solid Biosciences SLDB Stock Holding History

MetLife Investment Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$461K	Buy	46,157 +19,674	+74%	+$149K	﹤0.01%	1951
2026 Q1	$191K	Buy	+26,483	New	+$170K	﹤0.01%	2256
2024 Q4	–	Sell	-13,699	Closed	-$95.5K	–	2853
2024 Q3	$95.5K	Buy	13,699 +7,719	+129%	+$62.6K	﹤0.01%	2644
2024 Q2	$33.9K	Buy	+5,980	New	+$53.6K	﹤0.01%	2832
2019 Q1	–	Sell	-383	Closed	-$154K	–	2593
2018 Q4	$154K	Hold	383	–	–	﹤0.01%	2060
2018 Q3	$271K	Buy	+383	New	+$241K	﹤0.01%	1917

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's SLDB Position: Q2 2026 in Review

MetLife Investment Management increased its Solid Biosciences (SLDB) stake by 74% in Q2 2026, buying an estimated $149K and bringing the position to 46,157 shares worth $461K. The position accounts for ﹤0.01% of the portfolio, ranked #1951.

MetLife Investment Management first reported a position in SLDB in Q3 2018 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

MetLife Investment Management held 46,157 shares of Solid Biosciences worth $461K as of Q2 2026.
MetLife Investment Management bought 19,674 Solid Biosciences shares in Q2 2026, an estimated $149K.
Solid Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1951 holding.
MetLife Investment Management first reported a position in Solid Biosciences in Q3 2018 and has held it in 6 quarters since.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.